Concepts (239)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cell Cycle Proteins | 5 | 2020 | 230 | 1.830 |
Why?
|
| Pyrazoles | 4 | 2020 | 190 | 1.820 |
Why?
|
| Neoplastic Cells, Circulating | 11 | 2017 | 28 | 1.780 |
Why?
|
| Breast Neoplasms | 14 | 2019 | 1536 | 1.520 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2020 | 331 | 1.360 |
Why?
|
| Piperazines | 5 | 2019 | 206 | 1.350 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2019 | 332 | 1.300 |
Why?
|
| Triple Negative Breast Neoplasms | 4 | 2021 | 41 | 1.140 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2020 | 195 | 1.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2021 | 468 | 1.100 |
Why?
|
| Pyrimidinones | 2 | 2020 | 26 | 0.850 |
Why?
|
| Furans | 2 | 2021 | 27 | 0.840 |
Why?
|
| Pyrimidines | 2 | 2014 | 178 | 0.830 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2019 | 99 | 0.810 |
Why?
|
| Receptor, ErbB-2 | 6 | 2019 | 129 | 0.810 |
Why?
|
| Cell Survival | 3 | 2020 | 901 | 0.760 |
Why?
|
| Glioblastoma | 3 | 2019 | 219 | 0.750 |
Why?
|
| Cell Line, Tumor | 13 | 2020 | 1851 | 0.750 |
Why?
|
| Brain Neoplasms | 3 | 2019 | 371 | 0.700 |
Why?
|
| Quinazolines | 2 | 2019 | 70 | 0.700 |
Why?
|
| Disease-Free Survival | 7 | 2018 | 349 | 0.660 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2019 | 411 | 0.660 |
Why?
|
| Aromatase Inhibitors | 1 | 2018 | 17 | 0.620 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2019 | 231 | 0.620 |
Why?
|
| Autophagy | 3 | 2016 | 208 | 0.610 |
Why?
|
| Tamoxifen | 1 | 2018 | 62 | 0.610 |
Why?
|
| Epithelial-Mesenchymal Transition | 3 | 2015 | 135 | 0.590 |
Why?
|
| Drug Synergism | 5 | 2019 | 260 | 0.570 |
Why?
|
| Pasteurella Infections | 1 | 2015 | 5 | 0.520 |
Why?
|
| Pasteurella multocida | 1 | 2015 | 6 | 0.520 |
Why?
|
| Neoplastic Stem Cells | 3 | 2017 | 84 | 0.520 |
Why?
|
| Inflammatory Breast Neoplasms | 4 | 2017 | 5 | 0.520 |
Why?
|
| Bites and Stings | 1 | 2015 | 34 | 0.500 |
Why?
|
| Biomarkers, Tumor | 3 | 2012 | 508 | 0.470 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2014 | 4 | 0.470 |
Why?
|
| Mesothelioma | 1 | 2014 | 21 | 0.460 |
Why?
|
| Apoptosis | 3 | 2020 | 1641 | 0.460 |
Why?
|
| Bacteremia | 1 | 2015 | 155 | 0.440 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2013 | 63 | 0.440 |
Why?
|
| src-Family Kinases | 1 | 2013 | 91 | 0.430 |
Why?
|
| Cisplatin | 1 | 2014 | 192 | 0.430 |
Why?
|
| Nuclear Proteins | 2 | 2014 | 271 | 0.430 |
Why?
|
| Benzamides | 1 | 2013 | 156 | 0.410 |
Why?
|
| Neoadjuvant Therapy | 4 | 2021 | 104 | 0.380 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2017 | 756 | 0.380 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2017 | 536 | 0.350 |
Why?
|
| Calcium | 1 | 2013 | 929 | 0.340 |
Why?
|
| Humans | 33 | 2022 | 68618 | 0.330 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2009 | 60 | 0.330 |
Why?
|
| Female | 27 | 2022 | 38074 | 0.310 |
Why?
|
| Neoplasm Metastasis | 5 | 2017 | 306 | 0.290 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2019 | 304 | 0.280 |
Why?
|
| DNA Damage | 3 | 2020 | 190 | 0.280 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 1070 | 0.270 |
Why?
|
| Prognosis | 8 | 2017 | 2093 | 0.260 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2017 | 114 | 0.260 |
Why?
|
| Cell Cycle | 3 | 2019 | 312 | 0.250 |
Why?
|
| Phosphoproteins | 2 | 2017 | 202 | 0.250 |
Why?
|
| Middle Aged | 17 | 2022 | 21147 | 0.250 |
Why?
|
| Lung Neoplasms | 1 | 2014 | 1173 | 0.250 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2018 | 223 | 0.240 |
Why?
|
| Aged | 14 | 2022 | 14862 | 0.240 |
Why?
|
| Proportional Hazards Models | 4 | 2017 | 792 | 0.230 |
Why?
|
| Bone Neoplasms | 2 | 2014 | 100 | 0.210 |
Why?
|
| Polyneuropathies | 1 | 2022 | 6 | 0.210 |
Why?
|
| Muscular Diseases | 1 | 2022 | 41 | 0.200 |
Why?
|
| Tumor Burden | 2 | 2019 | 132 | 0.200 |
Why?
|
| Benzimidazoles | 2 | 2019 | 128 | 0.200 |
Why?
|
| Receptors, Progesterone | 4 | 2019 | 57 | 0.200 |
Why?
|
| Ketones | 1 | 2021 | 24 | 0.190 |
Why?
|
| Asbestos | 1 | 2020 | 7 | 0.190 |
Why?
|
| Neoplasm Staging | 4 | 2021 | 800 | 0.190 |
Why?
|
| Oncolytic Virotherapy | 1 | 2020 | 15 | 0.180 |
Why?
|
| MicroRNAs | 2 | 2017 | 447 | 0.180 |
Why?
|
| Oncolytic Viruses | 1 | 2020 | 17 | 0.180 |
Why?
|
| Pyridines | 2 | 2019 | 261 | 0.180 |
Why?
|
| Adenoviridae | 1 | 2020 | 295 | 0.170 |
Why?
|
| Risk Factors | 6 | 2017 | 5731 | 0.170 |
Why?
|
| Receptors, Estrogen | 3 | 2019 | 142 | 0.170 |
Why?
|
| Cell Proliferation | 3 | 2019 | 1174 | 0.170 |
Why?
|
| Phosphorylation | 2 | 2020 | 1200 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2019 | 24 | 0.170 |
Why?
|
| Thiophenes | 1 | 2019 | 76 | 0.170 |
Why?
|
| Adult | 13 | 2021 | 21403 | 0.170 |
Why?
|
| Estrogen Receptor alpha | 2 | 2013 | 65 | 0.170 |
Why?
|
| Imidazoles | 1 | 2019 | 175 | 0.160 |
Why?
|
| Protein Binding | 2 | 2019 | 1027 | 0.160 |
Why?
|
| Cancer Survivors | 1 | 2020 | 146 | 0.150 |
Why?
|
| Retrospective Studies | 6 | 2021 | 7277 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2018 | 36 | 0.150 |
Why?
|
| Neoplasms | 1 | 2009 | 1667 | 0.150 |
Why?
|
| Treatment Outcome | 6 | 2018 | 7029 | 0.150 |
Why?
|
| Anthracyclines | 1 | 2017 | 9 | 0.150 |
Why?
|
| Taxoids | 1 | 2017 | 41 | 0.150 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2018 | 118 | 0.150 |
Why?
|
| Animals | 6 | 2019 | 20881 | 0.140 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 170 | 0.140 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 378 | 0.140 |
Why?
|
| Cell Count | 2 | 2017 | 248 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2018 | 331 | 0.130 |
Why?
|
| Immunocompetence | 1 | 2015 | 19 | 0.130 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 4848 | 0.130 |
Why?
|
| Leukocyte Common Antigens | 2 | 2012 | 41 | 0.130 |
Why?
|
| Cell Nucleolus | 1 | 2015 | 14 | 0.130 |
Why?
|
| Dendritic Cells | 1 | 2017 | 201 | 0.130 |
Why?
|
| Biological Assay | 1 | 2016 | 88 | 0.130 |
Why?
|
| Texas | 2 | 2014 | 92 | 0.130 |
Why?
|
| Cats | 1 | 2015 | 292 | 0.120 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2014 | 50 | 0.120 |
Why?
|
| Cytokines | 2 | 2017 | 866 | 0.120 |
Why?
|
| Dogs | 1 | 2015 | 490 | 0.120 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2014 | 62 | 0.120 |
Why?
|
| Stress, Psychological | 1 | 2020 | 824 | 0.120 |
Why?
|
| RNA-Binding Proteins | 1 | 2015 | 215 | 0.110 |
Why?
|
| Mutation | 1 | 2019 | 1213 | 0.110 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2013 | 7 | 0.110 |
Why?
|
| Egtazic Acid | 1 | 2013 | 29 | 0.110 |
Why?
|
| Thapsigargin | 1 | 2013 | 18 | 0.110 |
Why?
|
| Inositol Phosphates | 1 | 2013 | 28 | 0.110 |
Why?
|
| Imatinib Mesylate | 1 | 2013 | 26 | 0.110 |
Why?
|
| Chromones | 1 | 2013 | 33 | 0.110 |
Why?
|
| Intracellular Space | 1 | 2013 | 42 | 0.110 |
Why?
|
| Morpholines | 1 | 2013 | 79 | 0.110 |
Why?
|
| Peptidylprolyl Isomerase | 1 | 2013 | 6 | 0.110 |
Why?
|
| Venous Thromboembolism | 1 | 2014 | 117 | 0.110 |
Why?
|
| Nomograms | 1 | 2013 | 19 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2013 | 33 | 0.110 |
Why?
|
| Epithelial Cell Adhesion Molecule | 1 | 2012 | 12 | 0.110 |
Why?
|
| Calcium Signaling | 1 | 2013 | 97 | 0.110 |
Why?
|
| Peptides | 1 | 2015 | 455 | 0.110 |
Why?
|
| Lymphopenia | 1 | 2012 | 12 | 0.100 |
Why?
|
| Antigens, Neoplasm | 1 | 2012 | 132 | 0.100 |
Why?
|
| Survival Rate | 2 | 2012 | 1056 | 0.100 |
Why?
|
| Immunohistochemistry | 2 | 2011 | 1174 | 0.100 |
Why?
|
| Signal Transduction | 3 | 2017 | 2689 | 0.100 |
Why?
|
| T-Lymphocytes | 1 | 2015 | 597 | 0.100 |
Why?
|
| Cell Adhesion Molecules | 1 | 2012 | 199 | 0.100 |
Why?
|
| Flow Cytometry | 1 | 2012 | 489 | 0.100 |
Why?
|
| Women's Health | 1 | 2012 | 148 | 0.100 |
Why?
|
| Comorbidity | 1 | 2015 | 1426 | 0.090 |
Why?
|
| Disease Progression | 4 | 2017 | 1038 | 0.090 |
Why?
|
| Mice | 2 | 2019 | 8474 | 0.090 |
Why?
|
| Neoplasm Proteins | 1 | 2012 | 307 | 0.090 |
Why?
|
| Follow-Up Studies | 2 | 2015 | 3259 | 0.090 |
Why?
|
| Aurora Kinases | 1 | 2009 | 3 | 0.090 |
Why?
|
| Retinoblastoma-Like Protein p130 | 1 | 2009 | 7 | 0.090 |
Why?
|
| Staurosporine | 1 | 2009 | 19 | 0.090 |
Why?
|
| Linear Models | 1 | 2011 | 521 | 0.090 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2021 | 129 | 0.080 |
Why?
|
| Risk Assessment | 2 | 2014 | 2007 | 0.080 |
Why?
|
| South Carolina | 1 | 2015 | 2752 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 1026 | 0.080 |
Why?
|
| Epithelial Cells | 1 | 2011 | 431 | 0.080 |
Why?
|
| Paclitaxel | 2 | 2019 | 140 | 0.080 |
Why?
|
| Time Factors | 2 | 2017 | 4655 | 0.070 |
Why?
|
| Breast | 2 | 2018 | 137 | 0.070 |
Why?
|
| Transcription Factors | 1 | 2011 | 753 | 0.070 |
Why?
|
| Estrogen Antagonists | 1 | 2005 | 10 | 0.070 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2005 | 15 | 0.070 |
Why?
|
| Bevacizumab | 2 | 2019 | 34 | 0.070 |
Why?
|
| Lymphatic Metastasis | 2 | 2017 | 274 | 0.060 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 546 | 0.060 |
Why?
|
| Male | 4 | 2022 | 37321 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 1046 | 0.050 |
Why?
|
| Muscle Weakness | 1 | 2022 | 26 | 0.050 |
Why?
|
| Critical Illness | 1 | 2022 | 191 | 0.050 |
Why?
|
| Network Meta-Analysis | 1 | 2019 | 5 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2022 | 344 | 0.040 |
Why?
|
| Everolimus | 1 | 2019 | 26 | 0.040 |
Why?
|
| Purines | 1 | 2019 | 39 | 0.040 |
Why?
|
| Aminopyridines | 1 | 2019 | 26 | 0.040 |
Why?
|
| Androstadienes | 1 | 2019 | 41 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2019 | 58 | 0.040 |
Why?
|
| Postmenopause | 1 | 2019 | 93 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2019 | 84 | 0.040 |
Why?
|
| Italy | 1 | 2017 | 36 | 0.040 |
Why?
|
| Ki-67 Antigen | 1 | 2017 | 29 | 0.040 |
Why?
|
| Nanog Homeobox Protein | 1 | 2017 | 6 | 0.040 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2017 | 11 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 111 | 0.040 |
Why?
|
| Receptors, Chemokine | 1 | 2017 | 26 | 0.040 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2017 | 20 | 0.040 |
Why?
|
| Adaptive Immunity | 1 | 2017 | 37 | 0.040 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2017 | 88 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2017 | 156 | 0.030 |
Why?
|
| Carcinogenesis | 1 | 2017 | 124 | 0.030 |
Why?
|
| G1 Phase Cell Cycle Checkpoints | 1 | 2015 | 12 | 0.030 |
Why?
|
| Dacarbazine | 1 | 2015 | 32 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 369 | 0.030 |
Why?
|
| Anura | 1 | 2015 | 9 | 0.030 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2015 | 57 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2017 | 447 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 714 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 931 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2014 | 3705 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 880 | 0.030 |
Why?
|
| Tubulin | 1 | 2015 | 60 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2015 | 294 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2015 | 261 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2015 | 532 | 0.030 |
Why?
|
| Protein Transport | 1 | 2015 | 280 | 0.030 |
Why?
|
| Chickens | 1 | 2015 | 232 | 0.030 |
Why?
|
| Zebrafish | 1 | 2015 | 187 | 0.030 |
Why?
|
| Cell Movement | 1 | 2017 | 630 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2015 | 852 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2015 | 213 | 0.030 |
Why?
|
| Young Adult | 2 | 2015 | 5717 | 0.030 |
Why?
|
| NIMA-Interacting Peptidylprolyl Isomerase | 1 | 2013 | 7 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 212 | 0.030 |
Why?
|
| Serine | 1 | 2013 | 99 | 0.030 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2013 | 204 | 0.030 |
Why?
|
| Tomography, Emission-Computed | 1 | 2012 | 40 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2014 | 682 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2016 | 706 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2012 | 81 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2012 | 114 | 0.020 |
Why?
|
| Trastuzumab | 1 | 2011 | 17 | 0.020 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2011 | 22 | 0.020 |
Why?
|
| Twist-Related Protein 1 | 1 | 2011 | 13 | 0.020 |
Why?
|
| Snail Family Transcription Factors | 1 | 2011 | 31 | 0.020 |
Why?
|
| Binding Sites | 1 | 2013 | 631 | 0.020 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2011 | 18 | 0.020 |
Why?
|
| CD24 Antigen | 1 | 2011 | 6 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2015 | 1342 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2011 | 94 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2011 | 151 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2011 | 157 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2011 | 217 | 0.020 |
Why?
|
| Hyaluronan Receptors | 1 | 2011 | 142 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2014 | 1553 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2011 | 239 | 0.020 |
Why?
|
| Risk | 1 | 2011 | 563 | 0.020 |
Why?
|
| Biomarkers | 1 | 2014 | 1593 | 0.020 |
Why?
|
| Phenotype | 1 | 2011 | 947 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 1465 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2011 | 1664 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2011 | 2673 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2005 | 562 | 0.010 |
Why?
|
| United States | 1 | 2012 | 7367 | 0.010 |
Why?
|